(Q40793025)

23 September 2017

title

Down-regulation of human alloimmune responses by genetically engineered expression of CD95 ligand on stimulatory and target cells (English)

1 reference

23 September 2017

Dulat HJ

1

1 reference

23 September 2017

von Grumbkow C

2

1 reference

23 September 2017

Baars W

3

1 reference

23 September 2017

Schröder N

4

1 reference

23 September 2017

Wonigeit K

5

1 reference

23 September 2017

Schwinzer R

6

1 reference

23 September 2017

language of work or name

English

0 references

publication date

1 July 2001

1 reference

European Journal of Immunology

23 September 2017

published in

1 reference

23 September 2017

volume

31

1 reference

23 September 2017

issue

7

1 reference

23 September 2017

page(s)

2217-2226

1 reference

Unraveling immune privilege

23 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2F1521-4141%28200107%2931%3A7%3C2217%3A%3AAID-IMMU2217%3E3.0.CO%3B2-E

Apoptosis, graft rejection, and transplantation tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1521-4141%28200107%2931%3A7%3C2217%3A%3AAID-IMMU2217%3E3.0.CO%3B2-E

Fas ligand gene transfer to renal allografts in rats: effects on allograft survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1521-4141%28200107%2931%3A7%3C2217%3A%3AAID-IMMU2217%3E3.0.CO%3B2-E

Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1521-4141%28200107%2931%3A7%3C2217%3A%3AAID-IMMU2217%3E3.0.CO%3B2-E

Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1521-4141%28200107%2931%3A7%3C2217%3A%3AAID-IMMU2217%3E3.0.CO%3B2-E

Transplantation of CD95 ligand-expressing grafts: influence of transplantation site and difficulty in protecting allo- and xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1521-4141%28200107%2931%3A7%3C2217%3A%3AAID-IMMU2217%3E3.0.CO%3B2-E

Fas-ligand: privilege and peril

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1521-4141%28200107%2931%3A7%3C2217%3A%3AAID-IMMU2217%3E3.0.CO%3B2-E

Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1521-4141%28200107%2931%3A7%3C2217%3A%3AAID-IMMU2217%3E3.0.CO%3B2-E

T cell receptor signals enhance susceptibility to Fas-mediated apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1521-4141%28200107%2931%3A7%3C2217%3A%3AAID-IMMU2217%3E3.0.CO%3B2-E

Monoclonal antibody-mediated tumor regression by induction of apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1521-4141%28200107%2931%3A7%3C2217%3A%3AAID-IMMU2217%3E3.0.CO%3B2-E

Metalloproteinase-mediated release of human Fas ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1521-4141%28200107%2931%3A7%3C2217%3A%3AAID-IMMU2217%3E3.0.CO%3B2-E

Lymphotoxin beta, a novel member of the TNF family that forms a heteromeric complex with lymphotoxin on the cell surface

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1521-4141%28200107%2931%3A7%3C2217%3A%3AAID-IMMU2217%3E3.0.CO%3B2-E

Activation interferes with the APO-1 pathway in mature human T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1521-4141%28200107%2931%3A7%3C2217%3A%3AAID-IMMU2217%3E3.0.CO%3B2-E

Induction of antigen-specific immunosuppression by CD95L cDNA-transfected 'killer' dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1521-4141%28200107%2931%3A7%3C2217%3A%3AAID-IMMU2217%3E3.0.CO%3B2-E

Regulation of the proinflammatory effects of Fas ligand (CD95L).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1521-4141%28200107%2931%3A7%3C2217%3A%3AAID-IMMU2217%3E3.0.CO%3B2-E

CD28-mediated activation of resting human T cells without costimulation of the CD3/TCR complex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1521-4141%28200107%2931%3A7%3C2217%3A%3AAID-IMMU2217%3E3.0.CO%3B2-E

Multiple target cell killing by the cytolytic T lymphocyte and the mechanism of cytotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1521-4141%28200107%2931%3A7%3C2217%3A%3AAID-IMMU2217%3E3.0.CO%3B2-E

A role for CD95 ligand in preventing graft rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1521-4141%28200107%2931%3A7%3C2217%3A%3AAID-IMMU2217%3E3.0.CO%3B2-E

Fas Ligand-Induced Apoptosis as a Mechanism of Immune Privilege

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1521-4141%28200107%2931%3A7%3C2217%3A%3AAID-IMMU2217%3E3.0.CO%3B2-E

Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1521-4141%28200107%2931%3A7%3C2217%3A%3AAID-IMMU2217%3E3.0.CO%3B2-E

FasL--too much of a good thing? Transplanted grafts of pancreatic islet cells engineered to express Fas ligand are destroyed not protected by the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1521-4141%28200107%2931%3A7%3C2217%3A%3AAID-IMMU2217%3E3.0.CO%3B2-E

Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells--a mechanism of immune evasion?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1521-4141%28200107%2931%3A7%3C2217%3A%3AAID-IMMU2217%3E3.0.CO%3B2-E

Dendritic cells genetically engineered to express Fas ligand induce donor-specific hyporesponsiveness and prolong allograft survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1521-4141%28200107%2931%3A7%3C2217%3A%3AAID-IMMU2217%3E3.0.CO%3B2-E

10.1002/1521-4141(200107)31:7<2217::AID-IMMU2217>3.0.CO;2-E

21 January 2018

Identifiers

DOI

1 reference

23 September 2017

1 reference